(NASDAQ: CALC) Calcimedica's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.55%.
Calcimedica's earnings in 2026 is -$29,562,000.On average, 6 Wall Street analysts forecast CALC's earnings for 2026 to be -$19,805,846, with the lowest CALC earnings forecast at -$22,372,105, and the highest CALC earnings forecast at -$16,035,178. On average, 5 Wall Street analysts forecast CALC's earnings for 2027 to be -$34,633,466, with the lowest CALC earnings forecast at -$55,235,955, and the highest CALC earnings forecast at -$14,216,756.
In 2028, CALC is forecast to generate -$34,740,525 in earnings, with the lowest earnings forecast at -$54,618,793 and the highest earnings forecast at -$16,200,490.